Toronto, Ontario – TheNewswire – August 18, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is thrilled to announce that Ventripoint and ASCEND Cardiovascular, LLC  have developed a new integrated product.  Today’s announcement marks a significant milestone in Ventripoint’s commitment to the collaboration between the two companies. ASCEND fits perfectly into Ventripoint’s roadmap for innovation and is a key step in the company’s mission to improve patient’s lives and become the standard of care.  

ASCEND is seamlessly integrated with leading EHRs, and imaging systems.  Their existing technology has been installed at 1000+ top ranked healthcare facilities and 600+ health systems with approximately 50,000 users across the United States.  

Ventripoint has successfully and seamlessly integrated its specialized AI-powered 3D Echo software application with ASCEND’s diagnostic viewer, InView, and reporting application, Cardiovascular Structured Reporting.  This cardiovascular workflow product provides an end-to-end solution that rivals other products on the market.  It is streamlined, smart, and effective for cardiology reading, reporting, and diagnostics, thereby improving diagnosis and monitoring of fetal, pediatric, and adult congenital heart disease.  

“We are excited to embark on this collaborative journey with ASCEND Cardiovascular,” stated Dr. Alvira Macanovic, President & CEO of Ventripoint Diagnostics. “We see this collaboration evolving progressively in its possibilities.  We believe that by integrating Ventripoint’s technology in diagnostic medical imaging with ASCEND’s expertise in cardiology IT this will be a successful integrated product. The product will offer a seamless and comprehensive approach to diagnosing and treating cardiovascular conditions.”

After months of development, Ventripoint stands ready to successfully unveil this integrated product with its newest partner at the 8th World Congress of Pediatric Cardiology and Cardiac Surgery in Washington, DC later this month.

"This is an important milestone and validation of ASCEND’s commitment to providers caring for children with heart disease. We are excited to enable the routine, efficient use of Ventripoint's advanced 3D image analysis in pediatric cardiology," stated Dr. Jeff Soble, CEO of ASCEND.

As the collaboration between Ventripoint and ASCEND continues to evolve, both companies remain committed to driving innovation and excellence in cardiovascular health technology. This integrated product marks an exciting milestone in the advancement of cardiac care and solving today’s and anticipating tomorrow’s challenges.

About Ventripoint Diagnostics Ltd.

Ventripoint has become known for the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary AI technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.  Learn more:  www.ventripoint.com.

About ASCEND Cardiovascular

ASCEND Cardiovascular is a leader in innovating cardiovascular solutions that empower the provider community to improve cardiovascular care. Designed with openness in mind, their solutions integrate with EHRs, medical devices, and other systems to deliver seamless workflows that span procedure types and modalities. A complete cardiovascular solution, ASCEND provides structured reporting, image visualization, collaboration, and analytics that improve efficiency, outcomes, and ROI. With decades of experience and a practicing cardiologist at our helm, the ASCEND team brings unparalleled “know how” in cardiology workflow, collaboration, and IT offering limitless opportunities to improve clinical, operational, and quality performance. Learn more: www.ascendcv.com.

For further information, please contact:

Jonathan Robinson CFA

JRobinson@oakhillfinancial.ca

(416) 669-1001

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.